Analyst Ratings For Bellerophon Therapeutics Inc (NASDAQ:BLPH)
Today, HC Wainwright reiterated its Buy rating on Bellerophon Therapeutics Inc (NASDAQ:BLPH) with a price target of $3.00.
There are 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Bellerophon Therapeutics Inc (NASDAQ:BLPH) is Buy with a consensus target price of $3.00 per share, a potential 347.96% upside.
Some recent analyst ratings include
- 1/29/2019-Bellerophon Therapeutics Inc (NASDAQ:BLPH) had its Buy rating reiterated by HC Wainwright with a $3.00 price target
- 1/24/2019-Bellerophon Therapeutics Inc (NASDAQ:BLPH) has coverage initiated with a Buy ➝ Buy rating and $3.00 price target
- 4/17/2017-Bellerophon Therapeutics Inc (NASDAQ:BLPH) has coverage initiated with a Buy ➝ Buy rating and $4.50 price target
- On 1/25/2019 Naseem Amin, Director, bought 571,429 with an average share price of $0.70 per share and the total transaction amounting to $400,000.30.
- On 9/17/2018 Associates Iv L P Venrock, Major Shareholder, bought 210,000 with an average share price of $1.20 per share and the total transaction amounting to $252,000.00.
- On 9/14/2018 Associates Iv L P Venrock, Major Shareholder, bought 75,000 with an average share price of $1.23 per share and the total transaction amounting to $92,250.00.
- On 9/12/2018 Associates Iv L P Venrock, Major Shareholder, bought 475,000 with an average share price of $1.18 per share and the total transaction amounting to $560,500.00.
- On 9/10/2018 Associates Iv L P Venrock, Major Shareholder, bought 200,000 with an average share price of $1.22 per share and the total transaction amounting to $244,000.00.
- On 9/7/2018 Associates Iv L P Venrock, Major Shareholder, bought 160,000 with an average share price of $0.86 per share and the total transaction amounting to $137,600.00.
- On 9/5/2018 Associates Iv L P Venrock, Major Shareholder, bought 50,000 with an average share price of $0.85 per share and the total transaction amounting to $42,500.00.
About Bellerophon Therapeutics Inc (NASDAQ:BLPH)
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices for the treatment of cardiopulmonary diseases. The company offers INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and has completed Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis. Its products are also used for other pulmonary hypertension conditions. The company was founded in 2009 and is headquartered in Warren, New Jersey.
Recent Trading Activity for Bellerophon Therapeutics Inc (NASDAQ:BLPH)
Shares of Bellerophon Therapeutics Inc closed the previous trading session at 0,67 +0,010 1,52 % with 0.64 shares trading hands.
